- Home
- SPPP vs MCRB Comparison
SPPP vs MCRB Comparison
Compare SPPP & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPPP
- MCRB
- Stock Information
- Founded
- SPPP 2011
- MCRB 2010
- Country
- SPPP Canada
- MCRB United States
- Employees
- SPPP N/A
- MCRB N/A
- Industry
- SPPP
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- SPPP
- MCRB Health Care
- Exchange
- SPPP NYSE
- MCRB Nasdaq
- Market Cap
- SPPP 172.2M
- MCRB 103.7M
- IPO Year
- SPPP N/A
- MCRB 2015
- Fundamental
- Price
- SPPP $12.38
- MCRB $14.67
- Analyst Decision
- SPPP
- MCRB Hold
- Analyst Count
- SPPP 0
- MCRB 4
- Target Price
- SPPP N/A
- MCRB $73.67
- AVG Volume (30 Days)
- SPPP 183.3K
- MCRB 142.9K
- Earning Date
- SPPP 01-01-0001
- MCRB 08-12-2025
- Dividend Yield
- SPPP N/A
- MCRB N/A
- EPS Growth
- SPPP N/A
- MCRB N/A
- EPS
- SPPP N/A
- MCRB 8.98
- Revenue
- SPPP N/A
- MCRB N/A
- Revenue This Year
- SPPP N/A
- MCRB N/A
- Revenue Next Year
- SPPP N/A
- MCRB N/A
- P/E Ratio
- SPPP N/A
- MCRB $1.61
- Revenue Growth
- SPPP N/A
- MCRB N/A
- 52 Week Low
- SPPP $8.55
- MCRB $6.53
- 52 Week High
- SPPP $11.39
- MCRB $30.60
- Technical
- Relative Strength Index (RSI)
- SPPP 62.92
- MCRB 76.40
- Support Level
- SPPP $11.57
- MCRB $10.67
- Resistance Level
- SPPP $12.68
- MCRB $15.98
- Average True Range (ATR)
- SPPP 0.26
- MCRB 1.41
- MACD
- SPPP -0.00
- MCRB 0.47
- Stochastic Oscillator
- SPPP 74.15
- MCRB 83.24
About SPPP SPROTT PHYS PLATINUM & PALLADIUM
Sprott Physical Platinum & Palladium Tr invests and holds all of its assets in physical platinum and palladium bullion. The company seeks to provide a secure, convenient, and exchange-traded investment alternative for investors interested in holding physical platinum and palladium bullion without the inconvenience that is typical of a direct investment in physical bullion. The Trust invests mainly in long-term holdings of unencumbered, fully allocated, physical platinum and palladium bullion.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.